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ABSTRACT 
To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-
activated ROCK2 [K14.ROCK
er
] were crossed to mice expressing epidermal activated ras
Ha  
[HK1.ras
1205
]. At 8 weeks, 4HT-treated K14.ROCK
er
-HK1.ras
1205 
cohorts exhibited 
papillomas similar to HK1.ras
1205
 controls; however, K14.ROCK
er
-HK1.ras
1205
 histotypes 
comprised a mixed papilloma/well-differentiated squamous cell carcinoma [wdSCC], 
exhibiting p53 loss, increased proliferation, and novel NF-κβ expression. By 12 weeks, 
K14.ROCK
er
-HK1.ras
1205 
wdSCCs exhibited increased NF-κβ and novel tenascin C, 
indicative of elevated rigidity; yet despite continued ROCK2 activities /p-Mypt1 inactivation, 
progression to SCC required loss of compensatory p21 expression. K14.ROCK
er
-HK1.ras
1205 
papillomatogenesis also required a wound-promotion stimulus, confirmed by breeding 
K14.ROCK
er
 into promotion-insensitive HK1.ras
1276
 mice, suggesting a permissive 
K14.ROCK
er
-HK1.ras
1205 
papilloma context [wound-promoted/NF-κβ+ve/p53-ve/p21+ve] 
preceded K14.ROCK
er
-mediated [p-Mypt1/tenascin C/rigidity] malignant conversion. 
Malignancy depended on ROCK
er
/p-Mypt1 expression, as cessation of 4HT-treatment 
induced disorganised tissue architecture and p21-associated differentiation in wdSCCs; yet 
tenascin C retention in connective tissue ECM suggests the rigidity laid down for conversion 
persists. Novel papilloma outgrowths appeared expressing intense, basal-layer p21 which 
confined endogenous ROCK2/p-Mypt1/NF-κβ to supra-basal layers, and was paralleled by 
restored basal-layer p53. In later SCCs, 4HT-cessation became irrelevant as endogenous 
ROCK2 expression increased, driving progression via p21 loss, elevated NF-κβ expression 
and tenascin C-associated rigidity; with p-Mypt1 inactivation/actinomyosin-mediated 
contractility to facilitate invasion. However, p21-associated inhibition of early-stage 
malignant progression and the intense expression in papilloma outgrowths, identifies a novel, 
significant antagonism between p21 and ras
Ha
/ROCK2/NF-κβ signalling in skin 
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carcinogenesis. Collectively these data show that ROCK2 activation induces malignancy in 
ras
Ha
-initiated/promoted papillomas in the context of p53 loss and novel NF-κβ expression; 
whilst increased tissue rigidity and cell motility/contractility help mediate tumour 
progression. 
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INTRODUCTION 
ROCK2, an effector of RhoA signalling downstream of ras
Ha
, plays essential roles in the  
regulation of actomyosin contraction and cellular tension during normal regulation of 
proliferation and differentiation.
1,2
 ROCK2 acts to regulate cellular motility through 
phosphorylation of LIM kinases (LIMK), myosin regulatory light chains (MLC2) and 
myosin-binding subunit to inhibit MLC phosphatase (Mypt1). Thus  in carcinogenesis, 
deregulated ROCK2 signalling and Mypt1 inactivation increases actomyosin-mediated 
cellular tension and collagen deposition that alters the extracellular matrix [ECM] to increase 
tissue rigidity,
3-8 
 alongside increased cell contractibility/motility that facilitates invasion.
4-6
  
This increased matrix density changes integrin clustering and increases proliferation via 
signalling through FAK downregulates GSK3β and increases β-catenin;5,6 whilst additional 
signal transduction pathways
9-12
 provide a matrix permissive for tumour progression.
4-6,13
  
 
This association with invasion and metastasis, plus the fact that ROCK proteins act as 
effectors downstream of ras signalling, make ROCK inhibition an attractive therapeutic 
target;
3,8
 particularly since ras-specific inhibitors have proved unsuccessful.
14
 However, few 
transgenic studies have directly explored activated ROCK2/ras
Ha
 synergism. Classic 
DMBA/TPA skin carcinogenesis employing 4HT-inducible ROCK2 mice [K14.ROCK
er
]
15
 
implicated synergism with ras
Ha 
activation
16
 as papilloma conversion rates increased;
5
 but 
given the numerous mutations elicited by DMBA initiation
16
 direct ROCK2/ras
Ha
 co-
operation remains unclear and potential synergism in earlier papillomatogenesis uncertain. 
Thus, to ratify ras/ROCK2 synergism, identify stage-specific causality and explore the 
unfolding progression mechanism, 4HT-inducible K14.ROCK
er
 mice were bred into a well-
characterised model of ras
Ha
-driven mouse skin carcinogenesis.
17-20 
 Here exclusive 
epidermal v-ras
Ha
 expression, induces wound-dependent, regression-prone papillomas 
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[HK1.ras
1205
] or epidermal hyperplasia alone [HK1.ras
1276
];
17
 phenotypes ideal to assess 
ROCK2/ras synergism in papilloma formation and malignant conversion/progression
17-20
 and 
assess effects on epidermal differentiation.
21,22
  
 
In this model, activated ROCK2/ras
Ha 
co-operation induced malignant conversion via p53
 
loss, 
increasing the numbers of proliferating cells prone to DNA damage; novel ROCK2-associated 
increase in NF-κβ expression; and elevated tenascin C, indicative of tissue rigidity. However, 
earlier ras/ROCK synergism in papilloma aetiology required both ras
Ha 
activation and a 
[wound] promotion stimulus. Furthermore, compensatory p21 expression in well-
differentiated SCCs inhibited early-stage malignancy, requiring p21 loss to progress to 
aggressive SCC. Cessation of 4HT treatment demonstrated that malignant conversion 
depended upon continued 4HT-mediated ROCK
er
/endogenous ROCK2 activation; however 
novel papilloma outgrowths appeared expressing intense p21 levels in proliferative basal 
layer keratinocytes that confined [endogenous] ROCK2/p-Mypt1/NF-κβ expression to supra-
basal, differentiating layers; accompanied by return of p53 expression to prevent relapse. 
These data confirm ras
Ha
/ROCK2 synergism drives both malignant conversion and malignant 
progression, and identify a significant antagonism between p21 responses following p53 loss 
and ROCK2/NF-κβ/tenascin C signalling in rasHa skin carcinogenesis.   
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RESULTS 
ROCK2 activation co-operates with ras
Ha
 to elicit malignant conversion but a tumour 
promotion stimulus is required to develop papillomas.   
To investigate deregulated ROCK2 signalling synergism with ras
Ha
 activation in classic 
mouse skin carcinogenesis, K14.ROCK
er
 mice were initially bred into line HK1.ras
1205
 which 
expressed activated v-ras
Ha
 exclusively in transit amplifying keratinocytes of the epidermal 
basal layer and required a promotion stimulus [TPA/ear-tag wounding] to develop wound-
sensitive papillomas that do not spontaneously convert to malignancy.
17-19 
In addition to 
investigate the requirement for wound promotion, K14.ROCK
er
 mice were also  bred into a 
wound-insensitive HK1.ras
1276
 line which exhibits hyperplasia alone unless treated with TPA 
or acquires an additional appropriate oncogenic insult.
17-20
 In repeat experiments, performed 
over a 12 month period, cohorts of age-matched, bi-genic K14.ROCK
er
/HK1.ras
1205
, 
HK1.ras
1205 
and K14.ROCK
er
 siblings were treated with 4HT for 8-10wks (n = 12); 10-12wks 
(n =12) and 14-16wks (n = 8) respectively; with controls [n = 6 per cohort per experiment] 
receiving ethanol alone [Figure 1a-d]. At 8wks, K14.ROCK
er
/HK1.ras
1205
 and HK1.ras
1205
 
mice developed papillomas at the wounded ear tag site, with little overt difference between 
cohorts [Figure 1b vs 3c]. By week 12, in repeat experiments, all 4HT-treated 
K14.ROCK
er
/HK1.ras
1205 
mice typically exhibited a single keratotic tumour [wdSCC] at the 
treated and tagged ear site, culminating in larger, less keratotic, reddish tumour [SCC] by 14 
weeks; whereas all untreated K14.ROCK
er
/HK1.ras
1205 
or HK1.ras
1205
 controls exhibited 
standard papilloma clusters associated with HK1.ras
1205
 mice [Figure 1a]
17-19
. All 4HT-
treated K14.ROCK
er
/HK1.ras
1205
 followed this aetiology, unless mice lost the wound 
promotion stimulus from ear tags and if so regardless of treatment/genotype [n = 9], such 
tumours remained small or regressed [Figure 1d; Supplementary Figure S1].
17,18
 This 
requirement for a wound-promotion stimulus was directly assessed in 4HT-treated 
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K14.ROCK
er
/HK1.ras
1276
 mice [n= 9 per cohort]. In repeat experiments] these mice failed to 
develop overt papillomas regardless of ear-tag wounding, over the thrice-weekly/20wk 
treatment regime [Figure 1e]; although hyperplasia did increase in all 4HT-treated 
K14.ROCK
er
/HK1.ras
1276
 mice [n =18; Supplementary Figure S1]. 
 
At 8 weeks, untreated K14.ROCK
er
/HK1.ras
1205 
tumours exhibited a squamous cell papilloma 
histotype [Figure 1f] indistinguishable from 4HT-treated HK1.ras controls, with a well-
ordered, sequential keratinocyte differentiation pattern, and strong supra-basal keratin K1 
expression [see Figure 3g] indicative of benign tumours.
17-20
 However, all 4HT-treated 
K14.ROCK
er
/HK1.ras
1205
 tumours exhibited a mixed histotype of papilloma and well-
differentiated SCC [Figure 1g; n = 24], which by 12 weeks  progressed to uniform wdSCCs 
[Figure 1h;  n=24] possessing a disordered basal layer and strands of aggressive SCC [Figure 
1i and j]. In repeat experiments, by 14-16wks, all 4HT-treated K14.ROCK
er
/HK1.ras
1205 
tumours [n =16] progressed to aggressive SCC [see figure 2: panel 3]; whereas no evidence 
of malignant conversion was observed in untreated controls [n = 12] or HK1.ras [n =12].
17-19
 
Malignant conversion to wdSCC was confirmed by reduced keratin K1 expression
17-20
 
already apparent in 8wk tumours [Figure 1k], which  reduced further and was subsequently 
lost as wdSCCs [Figure 1l] on progressed to K1-negative SCCs [see time course, Figure 2 
panel 3]; whilst all control tumours exhibited a suprabasal K1 expression profile consistent 
with a papilloma histotype.
17-19
   
 
ROCK
er
/ROCK 2 isoform activation and Mypt1 inactivation drive malignant 
conversion; but ras
Ha
 activation is required for papillomatogenesis.  
To confirm temporal, stage-specific ROCK
er
 expression all biopsies were analysed for GFP
tag
 
expression together with endogenous ROCK2; whilst 4HT-mediated ROCK
er
/ROCK2 
activation were confirmed by phosphorylation of Mypt1
1-3  
[Figure 2]. Initially pre-malignant 
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stages were analysed comparing epidermal histotype and GFP
tag
, p-Mypt and ROCK2 isotype 
expression in 4HT-treated (Figure 2: Panel 1 a-d) and untreated (e-h) K14.ROCK
er
 mice or 
4HT-treated HK1.ras mice (i-l). As reported previously
5,15
 4HT-treated K14.ROCK
er
 mice 
exhibit mild hyperplasia without signs of papillomatogenesis [20wks], even after prolonged, 
thrice weekly treatments over nine months [Figure 2: Panel 1a]; whilst HK1.ras mice 
exhibited a more severe epidermal hyperplasia [Figure 2: Panel 1i].
17
 Exogenous ROCK
er 
expression was distinguished from endogenous ROCK2 via GFP
tag
 expression, absent in 
HK1.ras controls [Figure 2: Panel 1b and f vs j]. ROCK
er 
activation by 4HT treatment was 
confirmed via p-Mypt1 expression [Figure 2c] which appeared in all epidermal compartments 
including basal-layers; consistent with ROCK
er 
expression from the K14 promoter.
15 
In 
untreated controls, p-Mypt1 expression was low/undetectable whilst 4HT-treated, 
hyperplastic HK1.ras epidermis exhibited a low, supra basal p-Mypt1 expression profile 
[Figure 2: Panel 1k]. Analysis of endogenous ROCK2 expression and in 4HT-treated 
K14.ROCK
er
 cohorts, ROCK2-specific antibodies detected endogenous ROCK2 expression in 
spinous keratinocytes and weaker ROCK
er 
expression in proliferative basal-layers; as shown 
at a junction between 4HT-treated and untreated skin [Figure 2: Panel 1 d vs h]. Here, 4HT-
treated HK1.ras epidermis exhibited low, supra-basal ROCK2 expression, consistent with p-
Mypt1 staining [Figure 2: Panel 1l]. Given that ROCK2-specific antibodies detected 
exogenous ROCK
er 
expression in K14.ROCK
er
 basal layer keratinocytes following 4HT-
treatment whilst untreated skin or hyperplastic HK1.ras keratinocytes exhibited endogenous 
ROCK2 in supra-basal layers, it suggests that 4HT-treatment increased/stabilized ROCK
er
 
expression
15
 and that ROCK2 functions primarily in differentiated keratinocytes to provided 
the tensile strength to the spinous layers.
21,22
 K14.ROCK
er
, ROCK2 and HK1.ras expression 
profiles in proliferative, keratin mK14
+ve
 basal layers or differentiated, supra-basal, keratin 
mK1
+ve
 layers are summarised in Figure 2 [diagram 1].  
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In carcinogenesis, temporal analysis of both GFP
tag
 [Figure 2: Panel 2a and c) and p-
Mypt1(2b and f) gave similar results and confirmed K14.ROCK
er
 expression and activation 
in 4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas and carcinomas at 8 and 12 weeks 
respectively; whilst HK1.ras
1205
 papillomas were negative for GFP
tag
 expression and at 12 
weeks only low/supra-basal p-Mypt1 expression was observed [Figure 2e and f]. Temporal 
analysis of ROCK
er
/ROCK2 isoforms [Figure 2, panel 3a-f ] show strong, elevated 
expression in all epidermal compartments of papillomas [8wks], wdSCCs [12wks] and SCCs 
[16wks]; whereas 4HT-treated HK1.ras
1205
 [12wks] papillomas exhibit weak, supra-basal 
ROCK2 expression, similar to the levels shown in hyperplasia [panel 1]; consistent with 
supra-basal p-Mypt1 inactivation  [panel 2]. Temporal analysis of keratin mK1 expression 
[green vs mK14 (red)], employed to aid in histology assessment,
17-20
 shows that strong, 
supra-basal expression in benign HK1.ras papillomas becomes reduced in wdSCC/SCC nests 
and is lost on progression to invasive SCC [Figure 2: panel 3g-i]. 
 
p53 loss and increased proliferation predispose to malignant conversion; but persistent 
p21 correlates with ROCK
er
-activation to limit early-stage malignant progression 
To investigate mechanism(s) underlying K14.ROCK
er
/HK1.ras
1205
 carcinogenesis, a 
temporal, stage-specific analysis of p53 and p21 status was performed, and proliferation 
levels were determined via BrdU-labelling [Figure 3: panels 1-3]. At 8wks, treated 
K14.ROCK
er
/HK1.ras
1205
 tumours exhibited elevated p53 expression, with nuclear expression 
in basal layer keratinocytes [Figure 3: panel 1a and b], as observed previously in HK1.ras 
papillomas
20,23 
and untreated controls. However, all treated K14.ROCK
er
/HK1.ras
1205
 also 
exhibited areas of reduced p53 expression not seen in controls, beginning in basal layers 
giving a weaker, cytoplasmic expression in the post mitotic supra-basal layers  [Figure 3: 
panel 1c]. This expression profile was consistent with their reduced K1 expression and 
10 
 
propensity for malignant conversion [above, Figure 1g and k]; such that by 12wks, 100% of 
both wdSCCs [n=24]/SCCs [n=24] tested became p53 negative [Figure 3: panel 1d and e].  
 
In contrast, whilst elevated p21 expression was observed in all 4HT-treated and untreated 
K14.ROCK
er
/HK1.ras
1205
 papillomas [Figure 3: panel 2a]
20,23
 unlike p53 expression analysis, 
all 4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas and wdSCCs examined to date retained 
an elevated p21 expression profile [Figure 3: panel 2b-d], with clear persistent p21 expression 
in wdSCC basal layer nuclei [Figure 3: panel 2d]. This phenotype persisted until over the 
ensuing 4 week period, such [p21
+ve
/K1
+ve
] wdSCCs progressed to [p21
-ve
/K1
-ve
] aggressive 
SCCs as p21 expression was lost; beginning in basal layer cells, again giving a supra-basal, 
cytoplasmic expression profile in 14wk SCCs [Figure 3: panel 2e]. As p21 expression in 
wdSCCs often paralleled that of ROCK
er
-targeted
 
basal layers [Figure 3: panel 2c]; it 
suggests a direct antagonism between ROCK
er 
signalling and p21, an idea supported by the 
relative lack of a significant proliferation increase following conversion as determined by 
BrdU-labelling [below; panel 3]; plus the intriguing, intense p21 expression observed 
following cessation of 4HT treatment [Figure 5].  
 
Given previous studies detected deregulated ROCK2 signalling effected cell proliferation
5
 
plus indications of a ROCK
er
/p21 antagonism, cell proliferation rates were assessed in stage-
specific tumours via BrdU labelling [Figure 3: panel 3]. Consistent wild the mild hyperplasia 
observed, 4HT-treated K14.ROCK
er
 epidermis possessed a mitotic index approximately 
double that in normal 4HT-treated skins [Figure 3: panel 3a,b] but less than HK1.ras 
epidermis,
17-19
 which exhibited a greater degree of hyperplasia [Figure 3: panel 3c], and a 
labelling similar to untreated/treated HK1.ras papillomas [Figure 3: panel 3d; 22.00±1.75 vs 
16.00±1.70] or untreated K14.ROCK
er
/HK1.ras
1205
 controls  [19.50±1.70]. In contrast by 8 
weeks, 4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas possessed a significantly increased 
11 
 
proliferation rate [61.50 ± 1.25; p<0.05], consistent with p53 reduction/loss and larger 
papillomas [Figure 1a vs. d].  This subtle observation identifies a novel, earlier 
ROCK2/ras
1205
 synergism where increased proliferation results in papillomas prone to 
malignant conversion; however 4HT-treated K14.ROCK
er
/HK1.ras
1205
 wdSCCs exhibited 
only a moderate, insignificant increase in mitotic index (71.56±5.25), suggesting that  
persistent/nuclear p21 expression inhibited proliferation of basal wdSCC keratinocytes to 
help limit early-stage progression.
20,23,24
 
 
Malignant conversion and early progression depend on continued ROCK
er
/ROCK2 
expression and further highlights antagonism with p21.   
An advantage of the 4HT-inducible system is the ability to assess oncogene dependence via 
cessation of treatment [Figure 4]. Thus, in two cohorts [n=5] at 12 and 14 weeks treatments 
ceased and tumours were biopsied two weeks later [Figure 4: panel 1]. Typically at 12wks, 
4HT-treated K14.ROCK
er
/HK1.ras
1205
 mice exhibited pale, keratotic wdSCCs which by 
14wks became larger, less keratotic and well-vascularised, indicative of malignant 
progression [Figure 4: panel 1a and b]. After two weeks without 4HT, neither cohort 
exhibited the envisage regression in size, although the 12wk cohort exhibited increased 
keratosis; and both 12wk and 14wk K14.ROCK
er
/HK1.ras
1205
 cohorts exhibited new tumour 
outgrowths, necessitating termination [Figure 4: panel 1d and e]; whilst control papilloma 
clusters changed little during this period [Figure 4: panel 1c and f].  
 
A detailed analysis two weeks post 4HT cessation, found that earlier wdSCC cohorts [12wks] 
[Figure 4: panel 2a] exhibited areas of disturbed basal-layer architecture, with disorganised 
keratinocytes and intercellular spaces suggesting a loss of cell-cell integrity [panel 2b] and an 
increased acanthosis [expansion of the spinous layer] suggesting elevated differentiation; 
12 
 
whereas other areas appeared to be progressing to SSC [panel 2a: black vs yellow box]. 
Increasing K1 expression at these disorganised sites [panel 2c; white vs yellow box] also 
indicates a differentiation response, consistent with the appearance of elevated, basal layer 
p21expression
20,23,24
 throughout this tumour [panel 2d; black vs yellow box; and 2e]. 
However, unlike that observed in analysis of papilloma outgrowths [below], in this context 
p53 expression did not return [panel 2f]; a feature possibly due to elevated NF-κβ expression 
[see Figure 6] hence the differentiation response rather than aopoptosis.
23
 Typically following 
4HT cessation, ROCK2 antibody analysis found decreased  exogenous ROCK
er
/endogenous 
ROCK2 expression at these p21/K1
+ve
 sites and here expression became supra-basal also 
[panel 2g and h]. Nonetheless, such wdSCCs possessed unaffected areas [Figure 4: panel 2a,c 
and d, yellow boxed areas] which had little K1/p21 and here endogenous, basal-layer ROCK2 
expression was detected [panel 2i] and activity confirmed by elevated p-Mypt1 expression 
[see Figure 7]; suggesting ROCK activation was required to maintain malignancy at this 
specific wdSCC stage. 
 
Analysis of older K14.ROCK
er
/HK1.ras
1205
 tumours support this conclusion, and as the 14wk 
tumours example shown [taken at 16wks] comprised highly invasive SCC and residual 
wdSCC [Figure 4: panel 3a; white vs yellow boxed area) it allowed a direct comparison of 
SCC and wdSCC within the same tissue section. This demonstrated that K1-negative SCC 
histotypes had mow lost p21 on progression [Figure 4: panel 3b, c and f] and now exhibited 
elevated, basal-layer [endogenous] ROCK2 activation as determined by p-Mypt1 expression 
in the invasive SCC cells [panel 3d,e and g]. In contrast, residual wdSCC areas exhibiting 
disturbed tissue architecture, again expressed an increased K1/p21 profile and resultant basal-
to-supra-basal transition of endogenous ROCK2 expression [panel 3h-j] paralleled by 
reduced p-Mypt1 inactivation [Figure 7; below]. Thus, during the additional two weeks 
13 
 
before treatment cessation, wdSCCs had progressed to a state where endogenous ROCK2 
arose to substitute for 4HT-activated exogenous ROCK
er
 and continued to drive malignant 
progression, as observed in other tumour types. 
 
The intriguing lack of tumour regression exhibited by K14.ROCK
er
/HK1.ras
1205
 carcinomas 
following 4HT cessation was unexpected, and the novel tumour outgrowths in particular were 
carefully re-examined [Figure 5]. Biopsies of all such outgrowths revealed a papilloma 
histotype, surprisingly devoid of wdSCC/SCC and keratin K1 expression confirmed their 
benign histotype [Figure 5a-c]. One feature of this analysis was that such tumour outgrowths 
repeatedly exhibited unusually intense p21 staining [Figure 5d-h], and at these sites of intense 
p21 expression, another novel feature was the return of p53 re-expression [Figure 5i-l] as 
observed previously.
23
 Indeed, employing standard p21 staining techniques, this intense p21 
expression profile appeared unique to these specific K14.ROCK
er
/HK1.ras
1205
 papilloma 
outgrowths when compared to analysis of similar histotypes [Figure 3 above]. Given that in 
previous studies western analysis was compromised by varying levels of contaminating 
connective tissue and keratosis,
23
 an attempt to semi-quantify this aspect exploited p21 
antibody titration. In several experiments utilising sections from separate outgrowths [n = 6], 
found that a four-fold anti-p21 dilution (1/200) gave acceptable staining [Figure 5e-g] in all 
layers, including basal layer nuclei [Figure 5h]. However, whilst similar analysis performed 
in parallel confirmed the return of p53 expression, again observed in all layer and in basal 
layer nuclei [Figure 5i-l], the 1/200 anti-p53 dilution repeatedly failed to detect significant 
expression levels.  
Moreover, another striking characteristic was that whilst endogenous ROCK2 levels 
remained elevated compared to untreated K14.ROCK
er
/HK1.ras
1205
 papillomas [Figure 2: 
panel 1l and 3d], ROCK2 expression was now strictly confined to differentiated layers in p21 
14 
 
positive papillomas; a result paralleled by supra-basal p-Mypt1 expression [Figure 5m-p]. 
Collectively these data suggest that malignant conversion depended upon ROCK2 activation; 
given that 12wk wdSCCs exhibited a dependence on ROCK
er 
to maintain malignancy [Figure 
4: panel 2] and 14wk tumours progressed to SCC due to endogenous ROCK2 expression; 
whilst intense, compensatory p21 staining reinforces the idea of a significant p21-mediated 
antagonism to ROCK2/ras
Ha
 synergism in proliferative basal layers, which in this context, 
enables return of p53 to prevent a relapse into malignancy.
20,23,24
  
 
Analysis of NF-κβ expression in K14.ROCK
er
/HK1.ras
1205
 carcinogenesis identifies an 
early, ROCK2-dependent role.   
NF-κβ-dependent transcription is a major target of Rho signalling and may contribute to the 
stromal remodelling that drives tumour progression.
9,10,25
 Analysis of NF-κβ found that by 
8wks, 4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas exhibited expression in all layers, 
[Figure 6: panel 1a and b]. By 12wks, expression intensified, becoming prominent in the 
invasive fronts of wdSCCs, with many nuclear-positive basal-layer keratinocytes [Figure 6: 
panel 1c and d]. On progression to aggressive SCC, NF-κβ expression became condensed and 
increasingly nuclear [Figure 6: panel 1e-g], concomitant with increasing endogenous ROCK2 
and p21 loss [above]. In contrast, untreated K14.ROCK
er
/HK1.ras
1205 
papillomas [12wks; 
Figure 6: panel 1h] exhibited weak staining, suggesting NF-κβ expression depended upon 
4HT-activated ROCK
er
 signalling; an idea also supported by detectable NF-κβ in 4HT-treated 
K14.ROCK
er
 but not HK1.ras
1205
 hyperplasia [Figure 6: panel 1i and j] that express low 
endogenous ROCK2 levels [Figure 2: panel 1g and 3d].  
This association of NF-κβ with ROCK2 signalling was reinforced in 4HT-cessation 
experiments [Figure 6: panel 2]; although some stage-specific differences were observed. For 
instance, in wdSCC sections the areas of disturbed tissue architecture and increasingly 
15 
 
p21
+ve
/K1
+ve
 [Figure 4: panel 2a,c and d [black/white boxed areas], retained NF-κβ 
expression [Figure 6: panel 2a and b] despite the reduction in exogenous ROCK
er
 activation, 
thus possibly preventing the return of compensatory p53 expression.
25,26 
 However, the 
unaffected areas that now expressed elevated, endogenous ROCK 2 [Figure 4: panel 2a,c and 
d (yellow boxed areas); and 2i] also expressed elevated NF-κβ. Indeed following cessation, 
analysis of the later SSC [14wk] cohorts, found elevated NF-κβ expression [Figure 6: panel 
2c and d] directly paralleled this increased endogenous ROCK2 and was concomitant with 
reduced p21 [Figure 4: panel 3a-g]. In contrast, intensely p21
+ve
 papilloma outgrowths 
[Figure 5d-h] exhibited reduced NF-κβ levels with little basal-layer expression [Figure 6: 
panel 2e and f vs. panel 1b)]; consistent with the restricted, now supra-basal ROCK2 
expression [Figure 6: panel 2g]; and thus this reduced NF-κβ may facilitate the return of p53 
expression to these papilloma basal layers [Figure 5i-l]. Collectively, these data suggest a 
ROCK
er
-mediated NF-κβ expression associates with early-stage K14.ROCKer/HK1.ras1205 
papillomatogenesis and may help create the context for malignant conversion via effects on 
p53 expression
25,26
 and appears necessary for continued malignancy, given the observed 
susceptibility to elevated levels of p21 following cessation of 4HT treatment.  
 
Tenascin C analysis indicates increasing tissue/ECM rigidity associates with malignant 
conversion, calling for ROCK2-mediated p-Mypt1 expression to facilitate invasion.  
In normal tissues, ECM expression of tenascin C is low but levels increase during tumour 
progression and given the interrelationship between ROCK2-associated collagen deposition 
and resultant integrin-mediated in the extracellular matrix,
4-6
 tenascin C levels were analysed 
to assess stage-specific roles and whether expression reflected increased tissue stiffness.
27-29
  
4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas [8wks] expressed low tenascin C levels 
[Figure 7: panel 1a and b] whereas wdSCC/SCCs exhibited intense staining in carcinoma 
16 
 
tissue and elevated ECM staining in surrounding connective tissue [Figure 7: panel 1c-e]. 
Contol HK1.ras
1205
 papillomas expressed only weak tenascin C levels in connective tissue 
ECM, but of note, low-level tenascin C expression was routinely detected in dermal ECM of 
4HT-treated K14.ROCK
er 
hyperplasia unlike that of HK1.ras
1205
 [Figure 7: panel 1f-h]. 
Following 4HT cessation the 14wk cohorts of aggressive SCC histotypes displayed intense 
tenascin C expression in both tumour tissue and connective tissue ECM. In contrast, wdSCC 
histotypes no longer exhibited tenascin C in tumour tissue ECM but of note, repeatedly 
retained expression in connective tissue/ECM [Figure 7: panel 1i-k]. Novel papilloma 
outgrowths also possessed only sporadic patches of [supra-basal] tenascin C with weak 
dermal/ECM staining [Figure 7: panel 1l]. These data show tenascin C expression depended 
upon ROCK 2 activation and expression appeared significant post p53 loss/conversion; 
whereas expression in wdSCCs connective tissue ECM post 4HT cessation, suggests that 
once laid down at conversion, tissue rigidity persists in wdSCCs. 
Thus, to assess the requirement for cell contraction/motility on malignant progression p-
Mypt1 levels were analysed. As anticipated, in 4HT-treated K14.ROCK
er
/HK1.ras
1205
 
papillomas, elevated p-Mypt1 expression paralleled ROCK
er
 activation with levels prominent 
in the invasive fronts/nests of wdSCC/SCCs [above; Figure 7: panel 2a-c]. Following 4HT-
cessation, SSC areas show persistent p-Mypt1 expression paralleled increasing endogenous 
ROCK2 activities [above]; whilst wdSCC histotypes exhibit reduced expression, consistent 
with a lack of activated exogenous ROCK
er
 [Figure 7: panel 2d and e] and their inability to 
invade. In addition, whilst papilloma outgrowths displayed elevated p-Mypt1, expression was 
again confined to super-basal layers, alongside supra-basal ROCK2 due to intense basal-layer 
p21 expression. Hence, these data suggest that Mypt1 inactivation is necessary to facilitate 
changes in actinomyosin/MLC essential to give cells the motility necessary for subsequent 
invasion of tissues with increased rigidity. 
17 
 
DISCUSSION 
These data demonstrate direct co-operation between 4HT-inducible ROCK
er
 and ras
Ha
 
activation, such that by 10 weeks, 100% of K14.ROCK
er
/HK1.ras
1205 
papillomas progressed 
to wdSCC; whereas all untreated cohorts or controls lacked spontaneous malignant 
conversion.
17-20
 This synergism is consistent with accelerating DMBA/TPA chemical 
carcinogenesis employing K14.ROCK
er 
mice
5
 and identification of ROCK2-associated p-
Mypt1activities in human skin carcinomas
6
 and other cancer types.
7,8
 4HT-cessation 
experiments demonstrated that malignant conversion relied upon continued ROCK
er
 
activities, unless endogenous ROCK2 activities arose to maintain progression. Thus, 
deregulated Rho/ROCK2 activation maybe a common synergistic event in ras
Ha
-initiated 
carcinogenesis, hence the major efforts geared to developing ROCK inhibitors
3,8
 that may 
achieve the elusive Achilles heel of successful anti-ras
Ha
 therapies.
14
  
In terms of stage-specific roles, ROCK
er 
acts at the malignant conversion stage in 
K14.ROCK
er
/HK1.ras
1205 
cohorts with one caveat: the appropriate papilloma context had to 
be achieved prior to malignant conversion. This included reduction/loss of p53; novel NF-κβ 
expression, together with elevated tenascin C, indicative of altered ECM and increasing tissue 
stiffness. Another salient feature of K14.ROCK
er
/HK1.ras
1205 
papillomatogenesis was the 
necessity for a promotion stimulus, typically supplied by the ear-tag wounding; and a pre-
requisite for papilloma aetiology in HK1.ras
1205
 mice.
17-20
 Hence, if wound-associated 
promotion was lost, K14.ROCK
er
/HK1.ras
1205 
papillomas regressed. Indeed, the necessity for 
an appropriate promotion stimulus was demonstrated in HK1.ras
1276
 mice, a line insensitive 
to ear-tag wounding but sensitive to TPA
17,19
 and fos activation.
18
  Here, 4HT-treated 
K14.ROCK
er
/HK1.ras
1276 
cohorts failed to exhibit papillomas; despite a thrice weekly/20wk 
treatment regime. Nonetheless, in these 4HT-treated K14.ROCK
er
/HK1.ras
1276 
cohorts, the 
ROCK
er
-associated alterations in collagen deposition plus integrin/FAK/β-catenin expression 
18 
 
effects,
5,6
  resulted in an increased hyperplasia and highlighted an early synergism. However, 
in this tissue context K14.ROCK
er
/HK1.ras
1276 
 synergism did not provide a permissive 
environment leading to overt papillomas. Hence, new experiments add a constitutive 
promotion role via fos activation
20,30,31
 to investigate potential mechanisms of ROCK2/fos co-
operation. 
These data also show that ROCK2 deregulation alone was insufficient to produce tumours 
requiring ras
Ha
-mediated initiation
5,17
 and once in sync, in a permissive papilloma 
environment, the K14.ROCK
er
-associated features induced malignant conversion. This 
synergism included a spatial context to tumour progression, as ROCK
er
/ROCK2-activation in 
proliferative basal-layer keratinocytes was a prerequisite for malignant conversion and 
progression; otherwise untreated K14.ROCK
er
/HK1.ras
1205 
and control HK1.ras
1205 
papillomas typically displayed a weak endogenous ROCK2 expression profile, with weak p-
Mypt1 inactivation confined to post-mitotic, supra-basal layers. Cessation experiments 
support this idea also, as wdSCCs [12wks] relied on ROCK
er
 activation in proliferative basal 
cells to maintain malignancy, whereas novel papilloma outgrowths lacked basal-layer 
ROCK2/p-Mypt1 expression; whilst later SSCs had acquired endogenous ROCK2 
activation/p-Mypt1 inactivation in basal layers. Furthermore, as ROCK2 may contribute to 
intra-cellular tension/rigidity in normal epidermal differentiation giving tensile strength to 
spinous-layer keratinocytes,
21,22
 [manuscript in prep], the abrupt loss of basal ROCK
er
 
expression following 4HT-cessation may account for the increased differentiation marker 
expression observed in wdSCCs and alongside p21 expression
23,24
 induce a differentiation 
response; given the lack of p53 to induce apoptosis.
32 
  
Previously, such compensatory p53/p21 responses were found to be key features in the 
mechanism underlying malignant conversion and progression in this skin model.
20,23
 In 
respect to p53, all 4HT-treated K14.ROCK
er
/HK1.ras
1205
 cohorts lost expression prior to 
19 
 
conversion, beginning in papilloma basal layers. The increased mitotic index following p53 
loss and the lack of DNA repair would give rise to additional mutations in highly 
proliferative cells giving a susceptibility to malignant conversion.
32,33
 Indeed, as outlined 
below, these K14.ROCK
er
/HK1.ras
1205
 data suggest a mechanism involving p53 loss which 
links ROCK2-associated NF-κβ deregulation to the matrix remodelling that drives 
progression
34-37
 when coupled to GSK3β/β-catenin/WNT signalling effects.5,23,38  Overall 
however, the identification of p21-associated responses may be of most significance, as this 
appears to limit [early-stage] malignant progression in K14.ROCK
er
/HK1.ras
1205 
 
carcinogenesis as observed in another version of this model.
20,23
 Despite many observations 
that p21 expression is lost alongside that of p53,
40
 as p53 diminished in 
K14.ROCK
er
/HK1.ras
1205 
 papillomas, basal layer p21 expression increased and moreover, 
persisted in wdSCCs becoming eventually lost on progression to SCC.
20,23,41
 All wdSCCs 
exhibited persistent basal-layer p21 expression, which exactly paralleled K14.ROCK
er
/p-
Mypt1 expression suggesting that increased p21 is a common response to 
ras/ROCK
er
/ROCK2 activities. This feature also accounts for malignancy appearing within 
10 weeks but progression to SCC required an additional 4-6wks; necessitating both p21 loss 
and continued ROCK
er
/ROCK2 activities. A p21-ras
Ha
/ROCK2 antagonism is also suggested 
by the intense p21 expression observed in papilloma outgrowths following cessation of 4HT. 
Initially, p21 was elevated in K14.ROCK
er
/HK1.ras
1205
 and control papillomas, but appeared 
mainly supra-basal, consistent with roles in keratinocyte differentiation.
23,24
 However, the 
intense p21 expression was unprecedented
20,23
 and appears directly geared to restrict residual 
ROCK2/p-Mypt1 expression [and NF-κβ; below] to their differentiation roles in post-mitotic, 
supra-basal keratinocytes.
21,22
  
Previous studies support antagonism between p21 and ras
Ha
/ROCK2-mediated malignant 
progression
11,42
 as in vitro, Rho kinases functioned to block ras
Ha 
-induced p21 expression;
11
 
20 
 
yet activated Rho GTPases did not transform NIH3T3 cells; showing the necessity for ras
Ha
 
activation.
11
  Later studies demonstrated ROCK2 affected cyclin D1 activity by regulating 
p21 levels
12,42
 and given that p21-mediated inhibition of cyclin D1 was observed in tri-genic 
ras
1276/fos/Δ5PTENflx carcinogenesis,20  this reinforces stage–specific p21 responses to 
oncogenic signalling, geared to attempted restoration of cell-cycle control; hence the lack of a 
significant increase in mitotic index in K14.ROCK
er
/HK1.ras
1205
 wdSCCs compared to 
papillomas. Subsequently, as p21 dissipates during malignant progression, attempts to 
maintain chromosomal stability following p53 loss are circumvented
21,40,41
 and continued 
4HT-ROCK
er
 [or endogenous ROCK2 activation] adds ras
Ha
/ROCK2-mediated cell-cycle 
control failures e.g. increased cyclin D,
12,20
 too highly proliferative cells with increased 
susceptibility to mutations, and when overlaid with ROCK2/p-Mypt1-mediated changes to 
cell motility/tension/ECM, the result is accelerated invasion and metastasis.
7,8
 
Another major pathway implicated in K14.ROCK
er
/HK1.ras
1205
 carcinogenesis involves NF-
κβ25 and cross-talk between Rho signalling and canonical NF-κβ pathways9,10 again link to 
the compensatory p21/p53 responses
11,26
 observed in progression. NF-κβ signalling mainly 
associates with inflammatory responses, yet roles also regulate proliferation, apoptosis and 
cell migration.
25,43
 Constitutive NF-κβ overexpression is relatively common, particularly in 
breast carcinogenesis, making NF-κβ inhibitors another therapeutic avenue.44 4HT-treated 
K14.ROCK
er
/HK1.ras
1205
 papillomas and K14.ROCK
er
 hyperplasia exhibited elevated basal-
layer NF-κβ expression, absent in HK1.ras or control histotypes; suggesting early, ROCKer-
specific roles for NF-κβ deregulation. This 4HT-ROCKer –mediated NF-κβ expression is 
consistent with activation of NF-κβ by Rho-induced, nuclear translocation of p65/RelA; 
independent of Ras GTPases.
9,10
 Whether this is exerting a protective or oncogenic role in 
this context is unclear,
25
 but elevated NF-κβ inflammatory roles would be consistent with 
21 
 
wound promotion, currently associated with fos/Jun/AP1 activation;
45
 hence whether fos/AP1  
promotes via deregulation of NF-κβ is under investigation. 
In addition to inflammatory/wound-promotion roles driving papillomatogenesis, ROCK
er
-
associated NF-κβ expression may influence malignant conversion via circumventing the 
compensatory p53 responses.
26
 In papillomas, NF-κβ and the axis of ROCK2/FAK/β-
catenin
5,6
 may contribute to the demise of p53, given both NF-κβ26 and FAK-associated β-
catenin
38,46
 inhibit p53 expression. These papilloma data thus link NF-κβ with increased 
DNA mutations/chromosomal instability
25,39
 following p53 loss and associated p21 
inhibition
47
 [below]; and indirectly link ROCK2-mediated NF-κβ to stromal remodelling
25
 
thus accounting for effects previously observed on expression of ECM molecules such as 
tenascin C.
48,49
 One consequence of p53 loss leading to an altered matrix may involve down-
regulated microRNAs,
34
 such as miR-200 which regulates cell-cell adhesion molecules
35
 and 
effected ROCK signalling in gastric cancer.
36
 Of note, p53-mediated miR-200 expression 
depended upon AKT levels,
37
 consistent with p53 loss driving malignant conversion in tri-
genic HK1.ras/fos/Pten
flx
 carcinogenesis.
20
     
 
Early NF-κβ expression coupled to p53 down regulation in K14.ROCK
er
/HK1.ras
1205
 
papillomas
25,26
 would account for increased proliferation, possibly via the NF-κβ responsive 
element regulating cyclin D
43
 and, in sync with ROCK2/ras signalling,
12
 add to the increasing   
pool of cycling cells susceptible to DNA damage/chromosomal re-arrangements. Further 
following 4HT cessation, as wdSCCs retained NF-κβ expression which continued the 
inhibition of p53 it helps explain the lack of apoptosis
26,28
 and instead, the system attempts to 
implement a p21-mediated differentiation response
24
 leading to the confused/disturbed 
wdSCC architecture. Previously the combined p53 and p21 responses induced compensatory 
differentiation levels sufficient to prevent conversion,
23
 however, in K14.ROCK
er
/HK1.ras
1205
 
22 
 
papillomas, NF-κβ/p53 antagonism25,26 coupled to the axis of ROCK2-associated GSK3β 
inactivation/increased nuclear β-catenin5,6,38,46 circumvented the p53 arm.23  Nonetheless, 
whilst unable to prevent conversion, persistent p21 remained to inhibited early-stage 
progression,
20,23,41
 until lost, thus releasing ras
Ha
/ROCK2/NF-κβ synergism to drive 
progression further.  
The cessation experiments clearly demonstrated the ability of p21 to inhibit ROCK2-
mediated progression where intense p21 expression confined both ROCK2 and NF-κβ to 
post-mitotic, supra-basal keratinocytes. This latter result not only shows the requirement for  
ROCK
er
-mediated NF-κβ expression to facilitate progression, but also demonstrated that p21 
responses eliminated NF-κβ expression independent of ROCK2 signalling.44,47 Furthermore, 
down-regulation of NF-κβ paralleled increasing basal layer p53 expression26 which restored 
the p21/p53-mediated resistance to malignant conversion.
20,23
 Indeed, this direct p21-
mediated antagonism to NF-κβ signalling was recently demonstrated in liver carcinogenesis 
where p21 knockout was shown to be pivotal to progression following loss of NEMO, a 
major NF-kβ pathway regulator.47 Of relevance to K14.ROCKer/HK1.ras1205 carcinogenesis, 
p21 overexpression protected NEMO
Dhepa 
animals against DNA damage,
39,41
 whereas p21 
knockout accelerated hepato-carcinogenesis in bi-genic NEMO
Dhepa
/p21
null 
mice,
47
 thus 
implicating NF-κβ in chromosomal damage.33,39,41,45 
Most major consequences of ROCK2 activation alter the tumour microenvironment and 
establish a context permissive for stage-specific progression.
1,2,13
 Previous K14.ROCK
er
 
studies demonstrated ROCK-associated collagen deposition resulted in a stiffened ECM and 
increased tissue rigidity.
5
 Similarly human cutaneous SCCs demonstrated ROCK2/p-Mypt1 
staining correlated with MLC2 phosphorylation and actomyosin contractility;
6
 suggesting a 
mechano-transduction pathway facilitated progression by providing the mobility/flexibility 
23 
 
necessary to invade tissues with increased rigidity,
6-8
 ideas supported by analysis of tenascin 
C
28-30
 and p-Mypt1 inactivation.  
 
Tenascin C is a large ECM/molecule associated with alterations in rigidity that drive 
progression
27-29
 and previously linked with activated Rho/Rock and MAP Kinase 
signalling.
28,29
 Tenascin C expression reflects tumour aggression and metastatic  
potential
27,48-50
 and also associated with deregulated NF-κβ signalling48 and NF-κβ roles in 
inflammation.
49
 Early 4HT-treated K14.ROCK
er 
hyperplasia and K14.ROCK
er
/HK1.ras
1205
 
papillomas displayed weak tenascin C levels, despite ROCK
er
-associated NF-κβ expression, 
With time and/or p53 loss, increased tenascin C expression appeared in the ECM of both 
wdSCC and surrounding connective tissue, with intense staining appearing as wdSCCs 
progressed to SCC.
27-29,48-50
 The necessity of continued ROCK
er
 activities for tenascin C 
expression was shown by cessation experiments and again as endogenous ROCK2/p-Mypt1 
appeared, intense tenascin C returned in both tumour and connective tissue ECM to facilitate 
progression.
28,29
  However, following cessation tenascin C repeatedly persisted in connective 
tissue matrix, but not that of wdSCC tissue; suggesting that once laid down to facilitate 
conversion, increased tissue rigidity remained. Hence, following cessation ROCK
er
-
dependent wdSCC cells appeared unable to invade, giving rise to the disturbed architecture.  
 
This lack of invasion ability maybe due to loss of ROCK
er
 mediated p-Mypt1 expression
5,6
 
given that on continued 4HT treatment or rise of endogenous ROCK2, maintenance/return of 
p-Mypt1 restores p-Mypt1-mediated MLC2 phosphorylation giving increased actomyosin 
contractility
6
 and flexibility/motility for local invasion. Indeed, a feedback mechanism maybe 
established whereby anomalous ROCK2/p-Mypt1/MLC-mediated changes in local ECM, 
increase tissue rigidity via altered integrin/FAK/β-catenin signalling and in turn necessitate 
24 
 
ROCK2/p-Mypt1-regulated changes in actinomyosin/MLC expression to provide the motility 
necessary for transformed cells to invade tissues with increased rigidity.
6,13,28,30
  
 
Collectively these data demonstrate that in the appropriate context of late-stage, highly 
proliferative p53
-ve
/p21
+ve
/NF-κβ+ve papillomas, ROCK2 activation co-operates with rasHa 
activation to induce malignant
 
conversion. Further ROCK2 and ROCK associated-NFκβ are 
required to maintain malignant progression to SCC, alongside Mypt1 inactivation/and 
tenascin c mediated changes in the ECM/motility that facilitate invasion. However, persistent 
p21 expression is able to counter and inhibit early-stage malignant progression, and if 
exogenous ROCK activation was lost, significant p21-mediated responses induced a basal-to-
suprabasal change in ROCK2/NF-κβ/p-Mypt1 expression and this antagonism also restored 
p53 tumour suppressor gene functions. 
25 
 
METHODS 
Transgenic genotypes and tumour induction. 
Transgenic mice expressing a tamoxifen-regulated ROCK2/estrogen fusion protein 
[K14.ROCK
er
]
15
 were bred to mice expressing activated ras
Ha
 [HK1.ras]
17
 and maintained as 
heterozygous transgenes in promotion sensitive HK1.ras
1205
 or insensitive HK1.ras
1276
 
strains.
17
 PCR confirmed genotypes, employing primers: 
ROCK2 [fwd:5-CGACCACTACCAGCAGAACA-3; rev:5-GACGAACCAACTGCACTTCA-3]; 
HK1ras [fwd;5-GGATCCGATGACAGAATACAAGC-3;  
rev:5-ATCGATCAGGACAGCACACTTGCA-3]. ROCK2 protein activation was achieved by 
thrice weekly topical treatments of 4-hydroxytamoxifen [330ug 4-HT/20ul ethanol; Sigma] ears 
and back; control mice received vehicle alone. Each cohort comprised a minimum of 15 male 
and 5 vehicle controls in repeat experiments; maintained for up to six months. Due to tumour 
size, 4HT-cessation experiments employed 5 bi-genic animals treated at tagged-ear sites only, 
at 12 or 14 weeks and maintained for an additional two weeks respectively. All experiments 
adhered to UK regulations; PPL licenced to DAG. 
 
Histology, Immunofluorescence and Immunohistochemistry 
Skin biopsies were fixed in buffered formalin [24hrs @ 4
o
C] for H&E staining. For 
immunofluorescence, following antigen retrieval [5 mins. boil/10mM sodium citrate], 
paraffin sections were incubated [24hrs @ 4
o
C] with: rabbit anti-K1 [1:100 (Covance)] 
employing guinea-pig anti-K14 antibodies [1:400 (Fitzgerald)] to delineate 
epidermis/tumour. Expression was visualized via FITC-labelled anti-rabbit IgG [1:100; 
(Jackson Labs)] and counterstained with biotinylated goat anti-guinea pig 
[1:100]/Streptavidin-Texas Red [1:500; (Vector Labs)]. For BrdU labelling, mice were 
injected IP with 125 mg/kg 5-bromo-4-deoxyuridine [Sigma] 2 hours prior to biopsy. BrdU-
labelled cells were identified by incubation [24hrs @ 4
o
C] with FITC-conjugated anti-BrdU 
26 
 
[1:5(Becton Dickinson)] and counterstained for K14 [above]. For immunohistochemical 
analysis, following antigen retrieval, paraffin sections were incubated overnight with rabbit 
anti-p53 [1:50; sc#6243]; p21
WAF 
[1:50; #sc397] at varying dilutions of 1/50, 1/100 and 1/200 
in antibody titration experiments; ROCK2 [1:100; sc#5561 (Santa Cruz)], rabbit anti-
phospho-Mypt1
Thr696
 [1:50; Millipore]; rabbit anti-tenascin C [1:50;  #T2551(Sigma)], and 
rabbit anti-GFP [1:50; Clonetech] followed by HRP-conjugated goat anti-rabbit [1:100 
(Vector)] and visualised by DAB+ [Dako] staining. Photomicrographs employed Axiovision 
[Zeiss] image capture software. 
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 LEGENDS 
Figure 1. Analysis of K14.ROCK
er
/HK1.ras
1205
 carcinogenesis and requirement for tumour 
promotion stimuli. (a) 4HT-treated K14.ROCK
er
/HK1.ras
1205
 mice [14wks], exhibit 
carcinomas, whereas untreated controls exhibit papilloma clusters. (b) At 6wks, 4HT-treated 
K14.ROCK
er
/HK1.ras
1205
 papilloma formation is identical to (c) untreated cohorts. (d) 
Following loss of a wound promotion [ear-tag] stimulus, 4HT-treated 
K14.ROCK
er
/HK1.ras
1205
 papillomas regress, whilst (e) alternate, 4HT-treated K14.ROCK
er
/ 
HK1.ras
1276
 cohorts exhibit mild ear keratosis only; regardless of wound-promotion and lack 
papillomas [see supplemental data Figure S1]. (f) Untreated K14.ROCK
er
/HK1.ras
1205 
tumours exhibit a papilloma histotype, whereas (g) 4HT-treated [8/10wks] 
K14.ROCK
er
/HK1.ras
1205 
tumours possess mixed histotypes of wdSCC [boxed] and 
papilloma. (h) By week 12, 4HT-treated K14.ROCK
er
/HK1.ras
1205
 mice exhibit a uniform 
wdSCC histotype, with nests of aggressive SCC. (i) Higher magnification shows wdSCCs 
exhibit a ragged/disorganised basal layer indicative of invasion [arrows]; with (j) several 
mitotic figures [arrows] in strands of more aggressive SCC. (k) Immunofluorescence analysis 
of K1[green]/K14[red] expression in 8/9wk 4HT-treated K14.ROCK
er
/HK1.ras
1205
 tumour  
shows papilloma [below line, left] with green suprabasal expression and red basal layer 
expression of K14 counterstain;  [above line, right] converting papilloma exhibits reduced K1 
and a yellow tone. (l) 4HT-treated K14.ROCK
er
/HK1.ras
1205
 wdSCCs [12wks] exhibit [right] 
reduced K1 and [left] increasing red tone on progression to K1
-ve
 SCC (bars: approx. i-k 
~100µm; f,g,h,and l ~50µm). 
Figure 2. Analysis of ROCK
er
 activation and ROCK 2 isoform expression in pre-neoplastic 
hyperplasia and temporal, stage-specific progression. Panel 1: Epidermal histotype and 
GFP
tag
, p-Mypt and ROCK2 isotype expression in 4HT-treated (a-d); untreated (e-h) 
K14.ROCK
er
 skin or 4HT-treated HK1.ras skin (i-l). (a) 4HT-treated K14.ROCK
er
 skin 
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[20wks] exhibits mild epidermal hyperplasia. (b) GFP
tag
 analysis confirms K14.ROCK
er
 
expression in basal keratinocytes; whilst (c) p-Mypt1 expression confirms ROCK
er
 activation. 
(d) Junction between 4HT-treated/untreated skin shows ROCK2-specific antibodies detect 
endogenous ROCK2 in spinous and weak ROCK
er 
expression in basal-layer keratinocytes. (e) 
Untreated K14.ROCK
er
 control exhibits normal epidermis; (f) positive for GFP-tag but (g) 
little p-Mypt1 expression with (h) spinous/granular layer ROCK2 expression. (i) Control 
4HT-treated HK1.ras
1205
 skin [4wks] exhibits increased hyperplasia; that (j) lacks GFP
tag
 and 
(k) exhibits weak, supra-basal p-Mypt1 or (l) supra-basal ROCK2 expression. Diagram 
indicates epidermal proliferative and differentiating layers and summary of K14.ROCK
er
 and 
HK1.ras expression in proliferative, keratin mK14
+ve
 basal layer keratinocytes and supra-
basal endogenous ROCK2 expression in differentiated, keratin mK1
+ve
 keratinocytes [bars: 
~40µm (d and h); 60µm (e-g; j-k); and 100µm (a-c,l)]. Panel 2: Expression of GFP
tag
 (a,c,e) 
and p-Mypt1(b,d, and f) in 4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas and 
carcinomas. ROCK
er
 expression was confirmed by detection of GFP
tag
 in (a) 4HT-treated 
wdSCCs [12wks] or (c) papillomas [8wks] and absent in (e) control 4HT-treated HK1.ras
1205
 
papillomas. (b) Elevated p-Mypt1 expression in wdSCCs [12wks] and (d) papillomas 
confirms ROCK
er 
 activation. (f) Control 4HT-treated HK1.ras
1205
 papillomas exhibit 
low/supra-basal p-Mypt1 expression [bars: 60µm (b and d); and 100µm (a,c,e, and f)]. Panel 
3: ROCK2 expression in 4HT-treated K14.ROCK
er
/HK1.ras
1205
 carcinogenesis. At low (a-c) 
and higher magnification (e and f) ROCK
er
/ROCK2 isoforms show strong, elevated 
expression in all epidermal compartments of (a) papillomas [8wks], (b) wdSCCs [12wks], (e) 
SCC nests  [12wks] and (c and f) uniform SCCs [16wks]. (d) 4HT-treated HK1.ras
1205
  
papillomas exhibit weak, supra-basal ROCK2 expression. (g-i) mK1 expression [green vs 
K14 (red)], indicative of benign vs malignant state, shows strong, supra-basal expression in 
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(g) benign HK1.ras papillomas; (h) reduced in wdSCC and (i) lost in SCC [bars  ~100µm: a-
d; g-i; ~50µm: e and f]. 
Figure 3. Analysis of p53, p21 and mitotic index expression in temporal, stage-specific 
tumour progression. Panel 1: p53 expression. (a) 4HT-treated K14.ROCK
er
/HK1.ras
1205
 
papillomas [8wks] show elevated p53 levels with (b) nuclear expression in basal layer 
keratinocytes. (c) Areas of converting 4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas 
[8wks] show p53 expression decreases in strands of basal layer nuclei. (d) wdSCCs [10-
11wks] exhibit barely detectable, cytoplasmic p53 expression in supra-basal layers. (e) SCCs 
[14wks] are devoid of detectable p53 expression. Panel 2: p21 expression. (a) 4HT-treated 
K14.ROCK
er
/HK1.ras
1205
 papillomas [8wks] show elevated p21 expression in all 
compartments. (b) p21 expression persists in wdSCCs [12wks] (c) with expression in 
ROCK
er
- targeted proliferative basal layers. (d) wdSCCs exhibit elevated, uniform p21 in 
basal and supra-basal layer nuclei. (e) SCCs [14wks] loose p21 expression, beginning in 
nuclei of invasive, disorganised SCC basal cells, resulting in low, supra-basal cytoplasmic 
expression. Panel 3: Immunefluorescence analysis of BrdU labelling and mitotic indices. (a) 
Hyperplastic 4HT-treated K14.ROCK
er
skin [8wks]. (b) Normal, untreated K14.ROCK
er
skin 
[8wks]. (c) 4HT-treated HK1.ras
1205
 skin [4 wks]. (d) 4HT-treated HK1.ras
1205
 papillomas 
[8wks]. (e) 4HT-treated K14.ROCK
er
/HK1.ras
1205
 papillomas [8wks] show increased 
numbers of BrdU positive cells similar to (f) 4HT-treated treated K14.ROCK
er
/HK1.ras
1205
 
wdSCCs [bars ~150µm: a; 100µm: d,e and f; ~50µm: c; ~25µm: b]. Panel 3: Mitotic indices; 
quantitation of labelled cells per mm basement membrane. Note: lack of a significant increase 
in 4HT-treated K14.ROCK
er
/HK1.ras
1205
 carcinomas (71.56 ± 5.25) vs. papillomas (61.50 ± 
1.25) [p = 0.561]. Cell proliferation rates were significantly lower in control papillomas 
[p=<0.05].  
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Figure 4. Cessation of 4HT treatment. Panel 1: Appearance of K14.ROCK
er
/HK1.ras
1205
 
tumours at 12wks, 14wks and 2 weeks following 4HT cessation. (a) Typical 4HT-treated 
K14.ROCK
er
/HK1.ras
1205
 mouse at 12wks exhibits a single wdSCC [~225mm
3
]. (b) At 
14wks, treated K14.ROCK
er
/HK1.ras
1205
 cohorts exhibit less keratotic, well vascularised 
SCCs [~324mm
3
]. (c) Treated HK1.ras
1205
 controls exhibit papilloma clusters [14wks]. (d) 
4HT cessation for 2 weeks in wdSCCs [12wk] cohorts show similar tumour size [~270mm
3
], 
with increased keratosis and novel tumour outgrowths. (e) SCC [14wk cohorts] also show 
little regression and become larger [~439mm
3
]; with novel tumour outgrowths.  
(f) HK1.ras
1205
 papilloma clusters remain unchanged [Black lines: plane of dissection; white 
line: approx.1cm]. Panel 2: Analysis of wdSCC [12wk] cohort 2 weeks post 4HT cessation. 
(a) wdSCC [Panel 1d] exhibits areas of disturbed tissue architecture [black box] alongside 
unchanged/SCC area [yellow box]. (b) At higher magnification black boxed area exhibits a 
disordered basal layer, intercellular gaps and increased acanthosis. (c) Increased K1 and (d) 
p21 expression appear at sites of disturbed architecture [white/black box]; but not 
wdSCC/SCC sites [yellow boxes]. (e) Elevated p21 expression appears in all layers, 
including ragged, basal layer nuclei; but [f] a serial section lacks detectable p53 expression. 
(g and h) ROCK2-specific antibodies show little ROCK
er
 expression in disorganised basal-
layers and endogenous ROCK2 is confined to supra-basal keratinocytes. (i) Areas of 
unchanged wdSCC/SCC exhibit elevated endogenous ROCK2 in all layers. Panel 3: Analysis 
of 14wk SCC cohort 2 weeks post cessation. (a) Tumour [panel 1e] shows a mix histotype of 
SCC [(b-f) large box] and wdSCC [(g-j) small box]. (b) SCC areas loose K1 expression and 
(c) p21 levels fade; whilst (d) ROCK2-specific antibodies detect elevated endogenous 
ROCK2 expression giving (e) persistent p-Mypt1 expression and (f) p21 is lost and (g) 
increased ROCK2 appears in fronts of invasive SCC keratinocytes. (h) Former wdSCC 
histotypes now exhibit elevated K1 with (i) elevated p21 in basal-layer nuclei. (j) Exogenous 
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ROCK
er
 fades and
 
endogenous ROCK2 expression becomes supra-basal. (bars: Panel 2: a,c 
and d ~200µm; g~150µm;  f and h ~100µm; e and  i~75µm; ; d ~50µm. Panel 3: a ~175µm; 
b-e ~100µm; h and j ~75µm; f and g ~50µm; and i ~30µm). 
 
Figure 5: Analysis of novel tumour outgrowths. (a) Typical tumour outgrowth from Figure 4 
panel 1d; line shows dissection plane] exhibits (b) typical benign papilloma histotype with (c) 
a standard, strong supra-basal K1 expression and typical basal-layer K14 counterstain. (d-h)  
Anti-p21 titration. (d) Employment of routine p21 antibody dilution (1/50) show novel 
papilloma outgrowths exhibit intense p21 expression in (e) both nuclei and cytoplasm of all 
tumour layers. (f) At 1/100 and (g) 1/200 dilution, elevated p21 expression is easily 
detectable again appearing in (h) basal layer nuclei and cytoplasm at 1/200 dilutions.  
(i-j) Anti-p53 antibody titration. (i) Routine p53 antibody dilution (1/50) demonstrates the 
return of increasing levels of novel p53 expression also detectable at (j) 1/100dil but not (k) 
1/200 dilution. (l) At routine 1/50 dilution, novel p53 re-expression is detected in nuclei and 
cytoplasm of all tumour layers. (m) Low and (n) high magnification show novel  papillomas 
express elevated ROCK2 proteins in supra-basal layers only, alongside (o) and (p) supra-
basal p-Mypt expression [bars: b and d ~150µm; c,f, i-k, m and o ~100µm;  c,h,n and p 
~50µm]. 
 
Figure 6. Analysis of NF-κβ expression in K14.ROCKer/HK1.ras1205 carcinogenesis. Panel 1: 
NF-κβ expression in 4HT-treated tumours. (a) Treated K14.ROCKer/HK1.ras1205 papillomas 
[8wks] display elevated NF-κβ expression. (b) Higher magnification [boxed area] shows 
expression in papilloma basal layer nuclei. (c) wdSCC [12wks] exhibit increased NF-κβ 
staining. (d) Higher magnification [boxed area] shows intense NF-κβ expression in both 
nuclei and cytoplasm of invasive cells. (e) Strong NF-κβ [14wks] is maintained in [p21ve/K1-
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ve
] aggressive, invasive SCC cells and (f) becomes less cytoplasmic with (g) strong nuclear 
expression. (h) Untreated K14.ROCK
er
/HK1.ras
1205 
papillomas [12wks] exhibit weak 
staining, with few cells expressing nuclear NF-κβ. (i) 4HT-treated K14.ROCKer hyperplasia 
express detectable NF-κβ sporadic nuclear expression in basal-layer keratinocytes. (j) 
HK1.ras
1205
 hyperplasia expresses little NF-κβ. Panel 2: NF-κβ expression following 
cessation of 4HT. (a) wdSCCs (serial section; Figure 4: panel 2a,c and d], shows elevated 
NF-κβ expression in all layers, with (b) persistent nuclear expression in areas of 
[p21
+ve
/K1
+ve
] disturbed architecture. (c) Invasive SCCs [14wk/2wk without 4HT; Figure 4: 
panel 3] exhibit elevated NF-κβ expression, paralleled by (d) elevated endogenous ROCK2 
expression. (e) At low and (f) higher magnification, papilloma outgrowths [serial sections 
from Figure 5] show reduced basal layer NF-κβ expression with few NF-κβ+ve nuclei, now 
confined to a supra-basal expression profile. (g) Endogenous ROCK2 parallels this p21-
restricted, supra-basal expression profile [bars: Panel 1 a and c ~200µm; b,d,e,h and j 
~100µm; f,g and I ~50µm; Panel 2: a,c-e and g ~100µm; b and f ~50µm]. 
Figure 7. Analysis of tenascin C and p-Mypt1 expression in K14.ROCKer/HK1.ras1205 
carcinogenesis. Panel 1: Tenascin C expression in 4HT-treated tumours. (a) Treated and (b) 
untreated K14.ROCK
er
/HK1.ras
1205
 papillomas [8wks] display low tenascin C levels except in 
sporadic dermal cells. (c) At 12wks wdSCC express elevated tenascin C in connective tissue, 
with patches of intense staining in carcinoma. (d and e) At higher magnification, intense 
tenascin C staining is prominent in supra-basal ECM, with elevated staining in the surrounding 
tissues. (f) 4HT-treated HK1.ras
1205
 papillomas [12wks] exhibit low tenascin C expression. (g) 
4HT-treated K14.ROCK
er 
hyperplasia exhibits tenascin C staining in dermal ECM unlike (h) 
early HK1.ras
1205
 hyperplasia. (i) Following 4HT cessation, wdSCC/SCCs [14wks; Figure 4 
panel 3] show (j) intense tenascin C staining in SCC ECM. (k) wdSCC histotypes loose 
tenascin C expression in tumour tissues but expression is retained in connective tissue ECM. 
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(l) Novel papilloma outgrowths [Figure 5] display patches of tenascin C and weak dermal 
ECM staining. Panel 2: p-Mypt1 expression in 4HT-treated tumours. (a) Treated 
K14.ROCK
er
/HK1.ras
1205
 papillomas [8wks] display elevated p-Mypt1 compared to (b) weak 
expression in untreated controls. (c) 4HT-treated wdSCCs exhibit increased p-Mypt1 
inactivation. Following 4HT cessation (d) ROCK2-positive SSC histotypes retain elevated p-
Mypt1 expression [boxed area; panel 1J] (e) ROCK2
er
 negative/ROCK2-suprabasal wdSCC 
histotype [boxed area, panel 1k] exhibits reduced supra-basal p-Mypt1. (f) Papilloma 
outgrowths display p-Mypt1 expression confined to [ROCK2/NF-κβ-positive] supra-basal 
layers [bar: Panel 1: c and i ~250µm; a,b and j-l ~150µm; d and f ~100µm; e,g and h 50µm. 
Panel 2: all ~100µm]. 
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